MedLab Clinical (ASX:MDC)

  • Symbol:ASX:MDC
  • Sector:Healthcare
  • Industry:Biotechnology
  • CEO:Dr. Sean Hall
  • Founded:2012

MedLab Clinical (ASX:MDC) Stock Price

MedLab Clinical (ASX:MDC) Company Overview

MedLab Clinical Limited (ASX:MDC) is a healthcare company with a focus on providing therapeutic pathways for chronic diseases. The company operates primarily out of Australia—with an organic chemistry set up in Southern California and additional offices in Malta and London—and has a market capitalisation of approximately $80 million.

MedLab is currently involved in the development of numerous medicinal products targeting everything from antibiotics to insulin, as well as therapies aimed at treating conditions such obesity and depression. However, it has been attracting serious attention for its research into cannabis-based medicine targeted at pain management—particularly chronic oncology pain—which is an increasingly lucrative field.

The company takes a research-driven approach to the market and has a diversified product offering which already includes several cannabinoid products such as NanaBis and NanaBidial. MedLab have also developed a nano-particle medicine delivery system known as Nanocelle, which is being applied to its medicines, off-patent drugs and nutritional products.

MedLab Clinical (ASX:MDC) Financials

More From MedLab Clinical...

Aussie Cannabis Stocks Quarterly Review
Medlab Records Strong Sales Revenue in Operations Update
Exclusive Interview with MedLab CEO Dr Sean Hall
Breaking Bud: Exclusive Interview with BuddingTech Founder Adam Miller

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.


Sean Hall
Chief Executive Officer & Managing Director
Sean Hall has more than 20 years’ experience in nutraceutical sales and development, along with early drug discovery in Australia, Asia and the US. He has been the leadership behind multiple patents, peer reviewed articles and product launches.

Hall is a Medical Doctor with an MBA in clinical pharmaceutical management, and was previously a founder of FIT-BioCeuticals, which became the most innovative, research driven, practitioner brand in Australia under his guidance.
Alan Dworkin
Chief Financial Officer
Alan Dworkin is a chartered accountant with over 18 years’ experience in the tax, retail, resources and nutraceutical/pharmaceutical industries.

He was the CFO and Company Secretary of FIT-Bioceuticals Limited for over six years, and is also a member of the Institute of Chartered Accountants in Australia, the Governance Institute in Australia and the Australian Institute of Company Directors.
Paul Vilner
Director of Commercial Operations
Paul Vilner has more than 20 years’ experience in the pharmaceutical industry in Australia, New Zealand and in the UK. He earned a Master of Research in Biotechnology, and is an honours graduate in both Chemistry and Biochemistry.

His diverse commercial experience includes sales, marketing, development, licensing, and acquisitions. Most recently, Vilner acted as General Manager for Tolmar ANZ.